Pulmatrix Inc (PULM) Stock Price, Quote & News

Company Profile

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clin...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 355 4440

Website: www.pulmatrix.com

Address:

945 Concord Street, Suite 1217, Framingham, United States

Canverra Nov. 14 at 3:10 PM

$PULM where is Jhonny ’Mondays’? no Monday announcement this week?

0 · Reply

Spudman7 Nov. 13 at 2:46 AM

$PULM Be on your toes. Think about the big picture when making your choices. This is all planned- you need to figure out what they have in store for retail. Algos and sequences have already been tested. GLTA

0 · Reply

Love_To_Learn Nov. 12 at 11:19 PM

$SLS coding batman robin initiating detonation sequence for market $PULM

5 · Reply

Nakom Nov. 12 at 9:30 PM

$PULM It’s just another manic merger Monday!!! That’s my fun day!!!

1 · Reply

hippo_hungry Nov. 12 at 9:12 PM

$PULM heavy volume today 😂..

0 · Reply

Love_To_Learn Nov. 12 at 8:56 PM

2.03 /2.-4 slip side $CYPH $SLS preparing the $PULM sequence

2 · Reply

Nakom Nov. 12 at 3:37 AM

$PULM I’m calling it one last time. This coming Monday is MERGEREERRRRRR MONNNNDDDDAAAYYY!!!!!

2 · Reply

BinaryMe Nov. 11 at 7:26 PM

$PULM things that make you go hmmmm 🤔 always to check back on ones you got out of in the green.

1 · Reply

Love_To_Learn Nov. 10 at 8:21 PM

$ENVB $PRPO $NUWE $SINT $PULM SHIFT

0 · Reply

Nakom Nov. 10 at 5:52 PM

$PULM I personally think they stopped Clofazimine because they have bigger fish to fry. To many other drugs out there that are billion dollar opportunistic. You have limited resources so put your money where the most income can be generated.

1 · Reply

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Aug 6, 2025, 8:05 AM EDT - 3 months ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

May 15, 2025, 8:05 AM EDT - 6 months ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 9, 2025, 4:00 PM EDT - 6 months ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Mar 21, 2025, 8:05 AM EDT - 8 months ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

ENTO

Nov 13, 2024, 9:00 AM EST - 1 year ago

Pulmatrix and Cullgen Announce Proposed Merger

Nov 8, 2024, 10:26 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 8:45 AM EDT - 1 year ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

May 15, 2024, 9:35 AM EDT - 1 year ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 10, 2024, 8:05 AM EDT - 1 year ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Jan 8, 2024, 9:00 AM EST - 2 years ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Nov 9, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 19, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Aug 23, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 10, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 11, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jun 15, 2023, 9:20 AM EDT - 2 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

May 24, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 12, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 2, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Supports World Asthma Day 2023

Mar 30, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Feb 6, 2023, 9:10 AM EST - 3 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Jan 25, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 23, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 4, 2023, 9:05 AM EST - 3 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Nov 10, 2022, 9:05 AM EST - 3 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 26, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Aug 8, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 12, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

May 12, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Mar 29, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 21, 2022, 12:45 PM EDT - 3 years ago

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Mar 21, 2022, 8:05 AM EDT - 3 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 17, 2022, 4:05 PM EDT - 3 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Feb 24, 2022, 4:05 PM EST - 4 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Issues Letter to Stockholders

Dec 17, 2021, 4:30 PM EST - 4 years ago

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Dec 15, 2021, 8:00 AM EST - 4 years ago

Pulmatrix Announces $6.75 Million Registered Direct Offering

Nov 10, 2021, 4:15 PM EST - 4 years ago

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 9, 2021, 9:00 AM EST - 4 years ago

Pulmatrix Announces Resolution of Contract Dispute with Cipla

Aug 10, 2021, 9:10 AM EDT - 4 years ago

Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update

Jul 27, 2021, 10:00 AM EDT - 4 years ago

Pulmatrix appoints Director Anand Varadan

May 11, 2021, 4:35 PM EDT - 4 years ago

Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update

Canverra Nov. 14 at 3:10 PM

$PULM where is Jhonny ’Mondays’? no Monday announcement this week?

0 · Reply

Spudman7 Nov. 13 at 2:46 AM

0 · Reply

Love_To_Learn Nov. 12 at 11:19 PM

$SLS coding batman robin initiating detonation sequence for market $PULM

5 · Reply

Nakom Nov. 12 at 9:30 PM

$PULM It’s just another manic merger Monday!!! That’s my fun day!!!

1 · Reply

hippo_hungry Nov. 12 at 9:12 PM

$PULM heavy volume today 😂..

0 · Reply

Love_To_Learn Nov. 12 at 8:56 PM

2.03 /2.-4 slip side $CYPH $SLS preparing the $PULM sequence

2 · Reply

Nakom Nov. 12 at 3:37 AM

$PULM I’m calling it one last time. This coming Monday is MERGEREERRRRRR MONNNNDDDDAAAYYY!!!!!

2 · Reply

BinaryMe Nov. 11 at 7:26 PM

$PULM things that make you go hmmmm 🤔 always to check back on ones you got out of in the green.

1 · Reply

Love_To_Learn Nov. 10 at 8:21 PM

$ENVB $PRPO $NUWE $SINT $PULM SHIFT

0 · Reply

Nakom Nov. 10 at 5:52 PM

1 · Reply

arrosto Nov. 10 at 1:53 PM

$PULM Maybe merger 2025 I hope

0 · Reply

Nakom Nov. 7 at 9:17 PM

$PULM I’m officially calling this coming Monday. Wait for it. Wait for it. MERGER MONDAAAY!!!

0 · Reply

HomeRunHitterXXXXX Nov. 7 at 7:53 PM

$PULM merger Monday? 😜

0 · Reply

HomeRunHitterXXXXX Nov. 7 at 7:41 PM

$PULM did they sell thier assets

0 · Reply

Nakom Nov. 7 at 4:25 PM

$PULM There is nothing here to see folks. Just go on you marry way. Have a great holiday season.

0 · Reply

Canverra Nov. 7 at 9:36 AM

$PULM some people still thinking assets are sold..this so secret that world would implode if this info comes to light LOL

1 · Reply

Nakom Nov. 6 at 9:26 PM

$PULM Games people play.

0 · Reply

HomeRunHitterXXXXX Nov. 6 at 8:29 PM

$PULM pos

0 · Reply

Nakom Nov. 6 at 4:52 PM

$PULM 3rd quarter earning calls are about done. That means whoever buys the assets does not have to disclose it until February 2026. It’s time now for merger Monday. Should be an interesting weekend.

0 · Reply

HomeRunHitterXXXXX Nov. 5 at 5:45 PM

$PULM wtf is going on with this. Where is some news?

0 · Reply

Nakom Nov. 4 at 8:18 PM

$PULM It’s not reverse merger Monday it’s reverse merger weekend. It’s all good.

0 · Reply

Nakom Nov. 3 at 5:23 PM

$PULM I’m calling this coming Monday MERGER MONDAY….! 🤣🤣🤣

0 · Reply

Market Cap	17.85M
Revenue (ttm)	7.81M
Net Income (ttm)	-9.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-122.41%
Debt to Equity Ratio	0.00

Volume	5,300
Avg Vol	12,492
Day's Range	N/A - N/A
Shares Out	3.65M
Stochastic %K	31%
Beta	1.64
Analysts	Strong Buy
Price Target	$10.00